Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Ronald J. Portman"'
Autor:
Susan McCune, Ronald J. Portman
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:869-872
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cddfdb4310b288301b3707e57b10b8d
https://doi.org/10.1007/s43441-022-00398-w
https://doi.org/10.1007/s43441-022-00398-w
Publikováno v:
Pediatric Hypertension ISBN: 9783031062308
Pediatric Hypertension ISBN: 9783319314204
Pediatric Hypertension
Pediatric Hypertension ISBN: 9783319314204
Pediatric Hypertension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c3a233cf8bf011d3d38a346202b4aa
https://doi.org/10.1007/978-3-031-06231-5_38
https://doi.org/10.1007/978-3-031-06231-5_38
Autor:
Susan, McCune, Ronald J, Portman
Publikováno v:
Therapeutic innovationregulatory science. 56(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::173af7d5569865e6100917144cf71d88
https://pubmed.ncbi.nlm.nih.gov/36103087
https://pubmed.ncbi.nlm.nih.gov/36103087
Publikováno v:
Journal of Data Science. 2:383-397
Decision making on diagnosis of hypertension is important to clinicians, patients and general public. We analyzed the agreement between clinic blood pressure (BP) measurements (individual or in combination) and ambulatory wake BP in the diagnosis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::782973ed0874c6896d452f427f1d7307
https://doi.org/10.6339/jds.2004.02(4).168
https://doi.org/10.6339/jds.2004.02(4).168
Autor:
Ronald J. Portman, Sebastian Weber, Kattayoun Kordy, Robert M. Nelson, Margaret Gamalo-Siebers, Lisa V. Hampson
Publikováno v:
Therapeutic Innovation & Regulatory Science. 53:567-578
The conduct of pediatric clinical trials is legally required, monitored, and encouraged in major geographic areas such as the United States and Europe. However, because pediatric patients are considered vulnerable populations, they should only be enr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d275bc861686389645a3a53dada07f5
https://doi.org/10.1177/2168479019842541
https://doi.org/10.1177/2168479019842541
Autor:
Edward M. Connor, Robert M. Nelson, Christina Bucci-Rechtweg, Dionna J Green, Ronald J. Portman, Thomas Miller, Gary J. Noel, Carmen Moreno, Donna L. Snyder, Collin Hovinga
Publikováno v:
Therapeutic Innovation & Regulatory Science
Including adolescents in adult clinical trials can play an important role in making innovative new medicines available to children in a timelier fashion. Stakeholders involved in the processes leading to regulatory approval and labeling of new drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52aa61ad078b0a88f730d1431a425a1f
https://pubmed.ncbi.nlm.nih.gov/33811302
https://pubmed.ncbi.nlm.nih.gov/33811302
Autor:
Susan McCune, Ronald J. Portman
Publikováno v:
Ther Innov Regul Sci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82cb18380c40ba95019ec19d84ed64d3
https://doi.org/10.1177/2168479019869754
https://doi.org/10.1177/2168479019869754
Autor:
Janina Karres, William V. Tamborlane, Paula H. Hale, Kathleen E. Bethin, Rose Gubitosi-Klug, Jeffrey L. Blumer, George P. Giacoia, Georgeanna J. Klingensmith, Paolo Tomasi, Morey W. Haymond, Michael D. Reed, R. Ravi Shankar, Ingrid Libman, Ronald J. Portman, David B. Dunger
Publikováno v:
Diabetes Care. 39:323-329
The Best Pharmaceuticals for Children Act of 2002 mandated that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) carries out critical reviews of the gaps in knowledge and unmet needs regarding safe and effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12084089d38563690a3fad7691884e19
https://doi.org/10.2337/dc15-1649
https://doi.org/10.2337/dc15-1649
Publikováno v:
Therapeutic innovationregulatory science. 47(5)
Confirmation of efficacy in pediatric drug development has traditionally required large, fully powered efficacy studies that have proven to have major feasibility and ethical challenges. Extrapolation of efficacy in the framework provided by the US F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c49be230b5934535efac25151792de
https://pubmed.ncbi.nlm.nih.gov/30235580
https://pubmed.ncbi.nlm.nih.gov/30235580
Autor:
Prince J. Kannankeril, Robert E. Shaddy, Dianne Murphy, Rachel D. Torok, Patricia Furlong, Andrew M. Atz, D. Dunbar Ivy, Danshi Li, Gail D. Pearson, Brian W. McCrindle, Ronald J. Portman, Thomas G. Diacovo, Daphne T. Hsu, Michael G. Hanna, Miriam Pina, Brigitte Lebeaut, Lisa Percival, Cathy Chen, Christoph Male, Eric M. Graham, Lisa A. Kammerman, Kevin D. Hill, Ellen Bolotin, Raafat Bishai, Pierre Mugnier, Jane W. Newburger, Jennifer S. Li, Timothy F. Feltes, John H. Lawrence, Norman Stockbridge, Robert Temple, Vasum Peiris, Stefanie Breitenstein, Gregory L. Kearns
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Children have historically been underrepresented or, indeed, omitted entirely, in drug trials, leading to a relative dearth of evidence in support of appropriate drug treatments for many pediatric diseases.[1][1], [2][2] Recent legislative initiative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cd2ba6e4ae71988837823ea2c2a6926
https://doi.org/10.1161/jaha.117.007283
https://doi.org/10.1161/jaha.117.007283